SESSIONS WILL BE DIVIDED INTO 3 TRACKS PRIOR TO THE EVENT. DELEGATES WILL BE FREE TO CHOOSE FROM TRACK 1, 2 or 3 AT ANY TIME.
THE DAY WILL START WITH NETWORKING AT 08:00 AND CONCLUDE WITH A NETWORKING SESSION FINISHING AT 17:00.
08:00 – 08:40
Networking
08:40 – 08:50
Welcome and opening remarks
Martino Picardo, Chairman, Discovery Park
08:50 – 09:10
An Interview With Steve Bates Chief Executive Officer, UK Bioindustry Association
Interview conducted by Martino Picardo, Chairman, Discovery Park
09:10 – 09:30
An Interview With Sean Marett Chief Business & Commercial Officer, BioNTech
Interview conducted by Martino Picardo, Chairman, Discovery Park
TREATMENT
The biotech sector is known for developing innovative treatments such as gene therapy, immunotherapy and drug delivery alternatives, but is this cost-effective? How can companies address the high cost of such technologies and get them to patients? Will biotechs have to think outside the box to secure funding in the future?
Positioning for growth is vital to the survival of a business, so are biotech companies asking themselves the right questions when looking to the future? How do they tackle business development, recruitment, location and marketing to ensure they are attractive to investors and their target market?
From accessing capital to selecting the right CDMO and planning your exit strategy, how do you build strategies for success? Can building in diversity derisk your programmes, platforms and products?
An Interview With Steve Bates Chief Executive Officer, UK Bioindustry Association
Interview conducted by Martino Picardo, Chairman, Discovery Park
09:00 – 09:30
An Interview With Sean Marett Chief Business & Commercial Officer, BioNTech
Interview conducted by Martino Picardo, Chairman, Discovery Park
TREATMENT
The biotech sector is known for developing innovative treatments such as gene therapy, immunotherapy and drug delivery alternatives, but is this cost-effective? How can companies address the high cost of such technologies and get them to patients? Will biotechs have to think outside the box to secure funding in the future?
Positioning for growth is vital to the survival of a business, so are biotech companies asking themselves the right questions when looking to the future? How do they tackle business development, recruitment, location and marketing to ensure they are attractive to investors and their target market?
From accessing capital to selecting the right CDMO and planning your exit strategy, how do you build strategies for success? Can building in diversity derisk your programmes, platforms and products?
CRISPR technologies provide much needed cures, but at a very high cost. Can we maintain the UK’s momentum in gene therapy with technologies like viral vectors?
FACILITATED BY
JONATHAN APPLEBY | Chief Scientific Officer | Cell and Gene Therapy Catapult (CGT Catapult)
PANELLISTS INCLUDE
DANIEL SMITH | Chief Scientific Officer & Industry Professor, School of Life Science | Cobra Biologics & University of Warwick JESÚS ZURDO | Global Head Bioproduction | Horizon Discovery MIKE SNOWDEN | Senior Vice President Discovery Sciences, Biopharmaceuticals R&D | AstraZeneca NATALIA NOVAC | Senior Director, Emerging Technology & Innovation, Corporate Business Development | Eli Lilly ANNA PERDRIX ROSELL | Co-founder and Managing Director | Sixfold Bioscience
ZAHID LATIF | Innovation Specialist, Life Sciences Organisation, International Trade & Investment Group | Department for International Trade
PANELLISTS INCLUDE
SHARON BROWNLOW | Chief Business Officer | Cell and Gene Therapy Catapult JAMES SPICER | Professor of Experimental Cancer Medicine | King’s College London MARK LEES | Vice President – Corporate Strategy and Operations | Mestag Therapeutics NEIL HAWKINS | Partner and Director, Visible Analytics | Professor of Health Technology Assessment, University of Glasgow ALLAN JORDAN | Director of Oncology Drug Discovery | Sygnature Discovery
SALLY WATERMAN| Chief Operating Officer | Medherant CHRISTIAN JONES| Chief Commercial Officer | Nanoform FAZ CHOWDHURY| Chairman and Chief Executive Officer | Nemaura PAUL STOTT| Chief Executive Officer | Seda Pharmaceutical Development Services ROS HANNEN| Founder and CEO | Keratify
JOE DE SOUSA | Senior Leader, Non-Exec Director and Independent Consultant | Melhor Consulting KEVIN COX | Chair | ValiRx FLIC GABBAY | Managing Partner | tranScrip LAURA ITZHAKI | Chief Scientific Officer | PolyProx Therapeutics CLARE TERLOUW | Head of Ventures | LifeArc
With life science space at a premium, where should you locate and grow?
FACILITATED BY
KATH MACKAY | Managing Director | Bruntwood SciTech – Alderley Park
PANELLISTS INCLUDE
SALLY ANN FORSYTH | Chief Executive Officer | Stevenage Bioscience Catalyst GLENN CROCKER | Head of Life Sciences & Chairman | JLL & BioCity Group MAYER SCHREIBER | Chief Executive Officer | Discovery Park DEREK JONES | Chief Executive Officer | Babraham Research Campus DOUG CUFF | Vice President of U.K. Real Estate | IQHQ
State of the nation, or should that be, what state is the nation in?
The COVID-19 pandemic has changed the UK business landscape, but has it been a blessing or a curse? Will the UK life sciences sector be in a stronger position to weather future upheaval due to Brexit, having adapted to a post-pandemic world?
FACILITATED BY
RICHARD HEBDON | Head of Health & Medicine, Ageing Society, Health & Nutrition Sector | Innovate UK
THOMAS OGORKA | Chief Executive Officer | Orphan Reach JENNY LAIRD | Vice President, Search & Evaluation Pain & Neurodegeneration | Eli Lilly and Company CHRISTOPHE MULLER | Global Head Business Development | Evotec DECLAN JONES | Vice President and Head of External Innovation (EI) and Scientific Licensing | Ferring Research Institute RICHARD WEAVER | Founder and Managing Director | XenoGesis CHARLES STEWARD | Patient Advocacy and Engagement Lead | Congenica
Staying private or going public? Which is best…. the view from the top?
Access to capital and liquidity are important factors for C suite and investors alike. However going public comes with a different set of pressures – regulatory, communication demands etc.
This session will address both private and public CEOs to ask what lessons have been learned and if they would do it all again.
From founding to funding and flourishing, how do we ensure our businesses reflect our demographic?
FACILITATED BY
TONY JONES | Chief Executive Officer | One Nucleus
PANELLISTS INCLUDE
RICHARD BUTT | Chief Executive Officer | Apollo Therapeutics JOANNA GOULD | Chief Executive Officer and Co-founder | VisusNano ELISABETH GOODMAN | Owner and Principal Consultant | RiverRhee Consulting
How do we make them economically feasible and scalable?
FACILITATED BY
IAN CAMPBELL | Interim Executive Chair | Innovate UK
PANELLISTS INCLUDE
KEITH THOMPSON | Chair, Pharma Advisory Board | Deep Science Ventures TIM LUKER | Vice President Emerging Technology and Innovation | Eli Lilly JAN THIRKETTLE | Chief Development Officer | Freeline LUCY FOLEY | Director of Biologics | CPI JONAS MOLLER | Chief Executive Officer | Albumedix MICHAEL HUNT | Chief Financial Officer | ReNeuron Group plc
Choosing your contract services partner – What does good look like?
The answer is ”it depends.” What is your ultimate business objective? Are you looking to take an entity from Candidate Selection all the way to the Market, or are you looking to add value and find a licensing partner?
FACILITATED BY
JO CRAIG | Senior Vice President CMC | KaNDy Therapeutics & NeRRe Therapeutics
PANELLISTS INCLUDE
STEPHEN TOOKER | Vice President, Commercial Packaging – Europe | PCI Pharma Services HELEN BARKER | Head of Pharmaceutical Development | Reneo Pharma JASON CAMERON | Senior Vice President, Global Technical Operations | Amicus Therapeutics ROGER KILBURN | Chief Executive Officer | Arcinova KRISHNA KANUMURI | Managing Director & Chief Executive Officer | Sai Life Sciences
